Regeneron Pharmaceuticals Inc. buy Evercore ISI
Summary
This prediction is currently active. The BUY prediction by Evercore_ISI currently has a performance of 17.83%. This prediction currently runs until 14.05.25. The prediction end date can be changed by Evercore_ISI at any time. Evercore_ISI has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | 0.140% | 0.140% |
iShares Core DAX® | 1.665% | 1.692% |
iShares Nasdaq 100 | -0.475% | 1.483% |
iShares Nikkei 225® | 2.620% | 4.475% |
iShares S&P 500 | -0.091% | 1.099% |
Comments by Evercore_ISI for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Evercore_ISI for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
16.05.24
16.05.25
23.08.24